Skip to content

The Science of the Art of Palliative Care

The Science of the Art of Palliative Care Pilot

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05137782
Enrollment
7
Registered
2021-11-30
Start date
2023-01-03
Completion date
2023-11-30
Last updated
2024-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Cancer, Gastrointestinal Cancer, Lung Cancer

Keywords

Palliative Care

Brief summary

This feasibility pilot study is designed to learn whether patients and their care partners (e.g., family members) are willing and able to complete two study visits at Dartmouth College while receiving cancer care at Dartmouth-Hitchcock Medical Center.

Detailed description

A feasibility pilot open label, single-arm observational case series of 10 patients with metastatic gastrointestinal and lung cancer patients and 10 care partners. Participants will complete two study visits, separated by approximately 8-16 weeks of usual oncologic care with early integrated specialty palliative care. The palliative care physician will also be a study participant. Primary Objective: To develop and refine study procedures which can be used in future research in order to further understanding of the mechanisms of action of specialty palliative. Expected products: manual of operating procedures and web-based data collection forms. Secondary Objectives: To test the feasibility of conducting a mechanism-focused clinical trial of primary palliative care vs. specialty palliative care for advanced cancer patients and their care partners. Expected products: preliminary data demonstrating the feasibility of study procedures sufficient to prove this study design is possible.

Interventions

Specialty palliative care, as opposed to primary palliative care.

Sponsors

Dartmouth College
CollaboratorOTHER
Dartmouth-Hitchcock Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * Patient: has received a diagnosis of advanced lung or gastrointestinal cancer within the last 24 weeks (note: advanced GI cancer will likely be pancreatic or colorectal) * Care partner: care partner of a patient who has received a diagnosis of metastatic lung or gastrointestinal cancer who has provided consent for study (either with our without functional MRI study visits) * Be able to understand study requirements and make an informed decision to participate * Be able to speak and read English

Exclusion criteria

* Life expectancy of \<8 weeks * Known brain metastases * Claustrophobia * Both patient and care partner refuse to participate in fMRI scan (ie., either patient or care partner must agree to an fMRI scan in order for either to participate) * Contraindications to MRI (e.g.: implanted or embedded metal/metal fragments. Metals in the body make the participant unable to undergo an MRI which makes them ineligible for study participation).

Design outcomes

Primary

MeasureTime frameDescription
Operationalization as measured by the creation of a manual of operating procedures and web-based data collection forms6 monthsEstablish acceptable operating procedures and data collection instruments which can be replicated for future projects.

Secondary

MeasureTime frameDescription
Feasibility as measured by enrollment number6 monthsPercent of participants approached and enrolled
Feasibility as measured by willingness to be randomized6 monthsPercent of participants enrolled and willing to be randomized
Feasibility as measured by procedure completion rate6 monthsPercent of participants randomized and completed procedures (specialty palliative care, fMRIs, surveys, bio response measurements).
Feasibility as measured by participant withdrawal rate6 monthsPercent of participants not completing each study visit and specialty primary care visit
Feasibility as measured by participant interest6 monthsPercent of participants approached and interested in participating
Tolerability as measured by rates of study procedure non-completion.6 monthsPercent of participants not completing each study procedures (specialty palliative care, fMRIs, surveys, bio response measurements).
Acceptability as measured by response to questions of level of burden.6 monthsTwo closed-ended Likert scale items regarding study burdensomeness. (this investigator-created instrument is in development)
Acceptability as measured by willingness to recommend study participation to others.6 monthsMeasured by the Net Promoter Score - The Net Promoter Score is an index that measures the willingness of participants to recommend a services to others. It is used as a proxy for gauging overall satisfaction with a service. Net Promoter Score (scale from 0 to 10 with 3 groups: promoters for 9-10, passive for 7-8 and detractor for below 6).
Tolerability as measured by subjective units of distress scores (SUDS, 0-100)6 monthsThe SUDs Rating Scale, or Subjective Units of Distress Scale (SUDs) as it is officially known, is used to measure the intensity of distress or nervousness in people with social anxiety. The SUDs is a self-assessment tool rated on a scale from 0 to 100.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026